In prostate cancer, the nuclear PRMT5 is responsible for proliferation inhibition and is related to the prolongation of survival rate while the cytoplasmic PRMT5 promotes cell proliferation (Lattouf et al., 2019). The gene discussed is PRMT5; the disease is prostate carcinoma.